cms.bioaccessla.com

Category: Navigating Regulatory Landscapes in Latin America

Explores the regulatory requirements and best practices for conducting clinical trials in Latin America, focusing on medical devices and biopharmaceuticals.

  • Biointelect Australia vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Biointelect into a search box, you are probably building a CRO shortlist. This article uses only what Biointelect publishes (www.biointelect.com/cro) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Biointelect publishes

    Biointelect is a Sydney consultancy founded in 2011 that added a CRO. It lists medical devices among its therapeutic areas, plus first-in-human, Phase I–II and high-risk inpatient studies, and leans toward strategy, local sponsor and regulatory work. Leah Goodman is CEO.

    Biointelect vs bioaccess®

    Dimension Biointelect bioaccess®
    Core focus Australian consulting + CRO + local sponsor First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial Australian market entry support: legal local sponsor, TGA submissions, Resident Director services and R&D Tax Incentive coordination Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If what you need is an Australian entity, local sponsor and R&D tax-incentive coordination around a Phase I unit, Biointelect fits.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Biointelect, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Biointelect features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Biointelect public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Datapharm Australia vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Datapharm Australia into a search box, you are probably building a CRO shortlist. This article uses only what Datapharm Australia publishes (datapharmaustralia.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Datapharm Australia publishes

    Datapharm Australia, in Drummoyne, Sydney, calls itself Australia's original full-service CRO, founded in 1987. Its therapeutic list includes devices, diagnostics and first-in-humans, and its cardiovascular page cites implants and stents. Helen Allars and John Edington are its co-founders.

    Datapharm Australia vs bioaccess®

    Dimension Datapharm Australia bioaccess®
    Core focus Mid-market single-country Australian CRO, drug and device First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial Phase IV post-marketing and observational studies, and pharmacovigilance services Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need a single-country Australian device or first-in-human study with a long-established local CRO, Datapharm fits.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Datapharm Australia, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Datapharm Australia features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Datapharm Australia public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • iNGENū CRO Melbourne vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed iNGENū CRO into a search box, you are probably building a CRO shortlist. This article uses only what iNGENū CRO publishes (ingenucro.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What iNGENū CRO publishes

    iNGENū CRO is a Melbourne, physician-led biotech CRO led by CEO Dr Sud Agarwal. It sells fixed-milestone pricing, claims costs 80–90% below US CROs and 30–60% below other Australian CROs, and about four-week ethics. In September 2025 it was named CRO for Sapu Nano's Sapu003 human trials.

    iNGENū CRO vs bioaccess®

    Dimension iNGENū CRO bioaccess®
    Core focus Lean Australian biotech CRO, drug-primary First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial FDA regulatory services and Phase 1–4 trials listed Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you are a lean US biotech looking for a low-cost Australian Phase 1, iNGENū is built for that.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including iNGENū CRO, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not iNGENū CRO features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the iNGENū CRO public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Accelagen Melbourne vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Accelagen into a search box, you are probably building a CRO shortlist. This article uses only what Accelagen publishes (accelagen.com.au) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Accelagen publishes

    Accelagen is a Melbourne regulatory and clinical firm founded in 2010 that can act as local sponsor. It markets to first-time and seed-stage sponsors of devices and small molecules. It publishes a case of ethics approval in 42 days for a US medical device company after two earlier rejections (sponsor not named), and first-in-human cases including Memo Therapeutics' anti-BKV therapy.

    Accelagen vs bioaccess®

    Dimension Accelagen bioaccess®
    Core focus Australian RA + CRO + local sponsor First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial Regulatory strategy, approvals and lifecycle-management planning across Asia-Pacific and North America Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If this is your first Australian trial and you want regulatory, local sponsor and CRO in one boutique, Accelagen fits.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Accelagen, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Accelagen features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Accelagen public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Southern Star Research Sydney vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Southern Star Research into a search box, you are probably building a CRO shortlist. This article uses only what Southern Star Research publishes (southernstarresearch.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Southern Star Research publishes

    Southern Star Research is a Sydney CRO founded in 2010 that runs full-service Phase I–IV work, positioned around early-phase biotech plus medical device clients. It claims 4–8 week start-up through Phase I unit relationships. Lloyd Prescott is CEO and Dr David Lloyd is founder and Managing Director. We found no named sponsor first-in-human press release on its site.

    Southern Star Research vs bioaccess®

    Dimension Southern Star Research bioaccess®
    Core focus Boutique Australian Phase I–IV CRO First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial Continuity from first-in-human through Phase II and pivotal Phase III Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you are a seed-to-Series B sponsor wanting an Australian specialist rather than a large CRO, Southern Star is a fair choice.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Southern Star Research, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Southern Star Research features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Southern Star Research public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Avance Clinical Australia vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Avance Clinical into a search box, you are probably building a CRO shortlist. This article uses only what Avance Clinical publishes (www.avancecro.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Avance Clinical publishes

    Avance Clinical is an Adelaide-headquartered biotech CRO, formerly the clinical arm of CPR Pharma, with operations in Australia, New Zealand, Asia, North America and Europe. In January 2025 Avance said it was CRO of record on more than 52% of active Phase I trials on ANZCTR and that more than 80% of its clients are US biotechs. It runs an Early Phase Center of Excellence that places studies into Australian Phase I units.

    Avance Clinical vs bioaccess®

    Dimension Avance Clinical bioaccess®
    Core focus Biotech full-service CRO, early phase First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you are a US biotech running an Australian Phase I drug trial, Avance is one of the most established choices.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Avance Clinical, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Avance Clinical features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Avance Clinical public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Linear Clinical Research Perth vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Linear Clinical Research into a search box, you are probably building a CRO shortlist. This article uses only what Linear Clinical Research publishes (www.linear.org.au · linear.org.au/about-us · linear.org.au/partner-with-us) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Linear Clinical Research publishes

    Linear Clinical Research is a not-for-profit early-phase organization in Perth, founded in 2010 by the Harry Perkins Institute of Medical Research with the WA Departments of Health and Commerce. It runs the Nedlands and Joondalup clinical trial centres and an Advanced Clinical Trial Centre, and says it has conducted more than 500 trials, including first-in-human, oncology and haematology studies. Its sponsor pages say 93% of its early-phase trials gained ethics approval in 4–6 weeks and 94.5% of its healthy-volunteer trials were dosed on time. We found no device study on its pages.

    Linear Clinical Research vs bioaccess®

    Dimension Linear Clinical Research bioaccess®
    Core focus Drug Phase I + first-in-patient oncology / haematology First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you are a drug or cell-therapy sponsor that wants a fast Australian Phase I, Linear is a strong option.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Linear Clinical Research, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Linear Clinical Research features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Linear Clinical Research public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • CMAX Adelaide Phase I vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed CMAX Clinical Research into a search box, you are probably building a CRO shortlist. This article uses only what CMAX Clinical Research publishes (www.cmax.com.au · www.cmax.com.au/about) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What CMAX Clinical Research publishes

    CMAX Clinical Research is an Adelaide early-phase unit established in 1993 at 21–24 North Terrace in the BioMed precinct. It says it has experience in more than 800 early-phase trials, specializes in first-time-in-human studies, and lists work ranging from cancer treatments to early-warning bio-devices. In 2025 CMAX and its Fusion Clinical Research division were acquired by New Zealand Clinical Research, and the combined NZCR Group reports more than 150 trial beds across New Zealand and Australia. CMAX publishes as a success story the first-ever human trial of Nacuity's NPI-001, run by its PI in 2017.

    CMAX Clinical Research vs bioaccess®

    Dimension CMAX Clinical Research bioaccess®
    Core focus Drug Phase I–II unit with unit-compatible device work First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need first-in-human for a drug or a simple device that needs confinement in a Phase I unit, CMAX is a credible choice.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including CMAX Clinical Research, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not CMAX Clinical Research features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the CMAX Clinical Research public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Nucleus Network Phase I vs a Latin America First-in-Human Device CRO (bioaccess®)

    If you typed Nucleus Network into a search box, you are probably building a CRO shortlist. This article uses only what Nucleus Network publishes (www.nucleusnetwork.com · www.nucleusnetwork.com/about) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Nucleus Network publishes

    Nucleus Network is an early-phase clinical trial operator that says it has run more than 2,500 trials since 1993. Its Australian Phase 1 clinics are in Melbourne (co-located with the Alfred Hospital), Brisbane (Royal Brisbane and Women's Hospital) and Sydney, its newest purpose-built unit in the Royal North Shore Hospital precinct, and it also runs a US unit in Minneapolis. It runs first-in-human, biosimilar, vaccine and patient studies for biotech and pharma sponsors, and we found no named sponsor on its pages. It is a drug Phase 1 operator, not a hospital implant device CRO.

    Nucleus Network vs bioaccess®

    Dimension Nucleus Network bioaccess®
    Core focus Drug Phase 1 clinic network First-in-human and early feasibility studies for medical devices
    Geography Australia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If your product is a drug, or a drug-device or wearable study that needs a 24/7 Phase I unit and healthy volunteers, Nucleus is a leading choice.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Nucleus Network, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Nucleus Network features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Nucleus Network public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Salud Solutions LATAM FSP vs a First-in-Human Device CRO (bioaccess®)

    If you typed Salud Solutions into a search box, you are probably building a CRO shortlist. This article uses only what Salud Solutions publishes (salud-solutions.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Salud Solutions publishes

    Salud Solutions is a family-owned Buenos Aires boutique CRO dedicated to Latin America since 1999. It specializes in Phase IV, observational and real-world evidence studies, plus functional-service (FSP) support. It has local CRAs in Argentina, Peru and Brazil, with additional coverage in Chile, Ecuador, Colombia, Mexico, and Central America and the Caribbean, and it handles import licenses for investigational product, kits and equipment, with local representation when the sponsor has no entity in the country. It says eight of its last fourteen studies were Phase IV, focused on oncology and respiratory. We found no device page on its site.

    Salud Solutions vs bioaccess®

    Dimension Salud Solutions bioaccess®
    Core focus LATAM late-phase / real-world evidence boutique CRO and FSP First-in-human and early feasibility studies for medical devices
    Geography Local CRAs in Argentina, Peru and Brazil; coverage in Chile, Ecuador, Colombia, Mexico, Central America and the Caribbean Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial Phase IV post-authorization studies, patient registries and real-world evidence Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need a late-phase, observational or real-world study in South America, or extra monitoring capacity on a regional study, Salud Solutions is built for that.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Salud Solutions, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Salud Solutions public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.